Latest From TransMolecular Inc.
TetraLogic Pharmaceuticals, a biopharmaceutical company developing drugs to treat cancer, has appointed Jonathan Lloyd Jones chief financial officer and vice-president of corporate development. From 2006 to 2010 Mr Lloyd Jones served as vice-president of finance at TransMolecular, and prior to that he was a senior director of corporate development at Genzyme.
Eisai has signed licensing and technology deals with two bioventures, both of which are aimed at strengthening its R&D activities in oncology, which the Japanese firm has positioned as a strategic therapeutic area amid patent expiries for its top product.
Topaz Pharmaceuticals has appointed Bob Radie president and chief executive officer. Dr Thomas Beck, who has been serving as interim CEO, will resume his role as chief medical officer. Mr Radie was most recently President and CEO of TransMolecular, a biotech company developing cancer diagnostic and treatment products. He has also previously served as Chief Business Officer at Prestwick Pharmaceuticals (which was acquired by Biovail in 2008) and Morphotek (acquired by Eisai in 2007). Topaz’s lead product is ivermectin topical cream, which is concluding Phase III trials to support an NDA for the treatment of head lice.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- TransMolecular Inc.
- Senior Management
- Contact Info
Phone: (610) 768-8041
1060 1st Ave.
King of Prussia, PA 19406
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.